Disease relevance of copper

• Cellular processing of copper-67-labeled monoclonal antibody chCE7 by human neuroblastoma cells [1].
• Copper-67 radioimmunotherapy and growth inhibition by anti-l1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis [2].
• CONCLUSION: Copper-67-labeled MAb35 is more favorable than its radioiodine-labeled counterpart for RIT of colorectal carcinoma due to higher tumor-to-blood ratios, but the problem of nonspecific liver and bowel uptake must first be overcome [3].
• Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma [4].

High impact information on copper

• Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595 [5].
• Possible approaches to these challenges, including high-dose radioimmunotherapy and chemotherapy followed by autologous bone marrow transplantation, the use of radionuclides such as yttrium 90 (90Y) and copper 67 (67Cu), and the development of humanized and bifunctional antibodies, are under investigation [6].
• Tumor uptake and metabolism of copper-67-labeled monoclonal antibody chCE7 in nude mice bearing neuroblastoma xenografts [7].
• Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice [8].
• Mouse brain synaptosomes accumulate copper-67 efficiently by two distinct processes independent of cellular prion protein [9].

Associations of copper with other chemical compounds

• Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer [10].

Gene context of copper

• Iodine-131, Yttrium-90, and Copper-67 labeled monoclonal antibodies targeting CD-20, CD-22, HLA class II, and other cell surface antigens have been tested and demonstrate higher overall response rates (50-80%) and complete response rates (20-40%) than unlabeled antibodies [11].

Analytical, diagnostic and therapeutic context of copper

• After purification by gel filtration, the antibody-porphyrin conjugates were labeled with copper-67 in aqueous solution [12].
• Copper-67-labeled Cu-PTSM was administered intravenously to four anesthetized dogs, followed c. 5 min later by a left ventricular injection of 85Sr-labeled microspheres (15 microns) to provide an independent measure of tumor perfusion [13].

References